Literature DB >> 34253876

Levo-tetrahydropalmatine inhibits α4β2 nicotinic receptor response to nicotine in cultured SH-EP1 cells.

Yuan-Bing Huang1,2, Ze-Gang Ma2,3, Chao Zheng2,4, Xiao-Kuang K Ma2,5, Devin H Taylor2,6, Ming Gao2, Ronald J Lukas2, Jie Wu7,8,9.   

Abstract

Nicotine, a major component of tobacco, is highly addictive and acts on nicotinic acetylcholine receptors (nAChRs) to stimulate reward-associated circuits in the brain. It is well known that nAChRs play critical roles in mediating nicotine reward and addiction. Current FDA-approved medications for smoking cessation are the antidepressant bupropion and the nicotinic partial agonist varenicline, yet both are limited by adverse side effects and moderate efficacy. Thus, development of more efficacious medications with fewer side effects for nicotine addiction and smoking cessation is urgently needed. l-Tetrahydropalmatine (l-THP) is an active ingredient of the Chinese medicinal herb Corydalis ambigua that possesses rich neuropharmacological actions on dopamine (DA) receptors in the mesocorticolimbic dopaminergic reward pathway. L-THP has been explored as anti-addiction treatments for drug abuse including nicotine. However, the targets and mechanisms of l-THP-caused anti-nicotine effects are largely unknown. In this study we address this question by elucidating the effects of l-THP on human neuronal nAChRs using patch-clamp recordings. Human neuronal α4β2-nAChRs were heterologously expressed in SH-EP1 human epithelial cells. Bath application of nicotine (0.1-100 μM) induced inward currents, co-application of l-THP (3 μM) inhibited nicotine-induced currents in the transfected cells. L-THP-caused inhibition was concentration-dependent (the EC50 values for inhibiting the peak and steady-state current were 18 and 2.1 μM, respectively) and non-competitive. Kinetic analysis of the whole-cell currents showed that l-THP slowed rising time and accelerated decay time constants. L-THP specifically modulated α4β2-nAChRs, as it did not affect α7-nAChRs or α1*-nAChRs (muscle type). Interestingly, two putative α4β2-nAChR isoforms, namely sazetidine A-activated, high-sensitive one (α42β23-nAChR) and cytisine-activated, low-sensitive one (α43β22-nAChR) were pharmacologically separated, and the low-sensitive one was more susceptible to l-THP inhibition than the high-sensitive one. In conclusion, we demonstrate that l-THP blocks neuronal α4β2-nAChR function, which may underlie its inhibition on nicotine addiction.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  SH-EP1 cells; acetylcholine receptors; levo-tetrahydropalmatine; nicotine addiction; patch-clamp recording; α4β2-nicotinic receptor

Mesh:

Substances:

Year:  2021        PMID: 34253876      PMCID: PMC8975845          DOI: 10.1038/s41401-021-00709-1

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  60 in total

Review 1.  l-tetrahydropalamatine: a potential new medication for the treatment of cocaine addiction.

Authors:  Jia Bei Wang; John R Mantsch
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.

Authors:  Mirko Moroni; Ruud Zwart; Emanuele Sher; Bruce K Cassels; Isabel Bermudez
Journal:  Mol Pharmacol       Date:  2006-05-23       Impact factor: 4.436

3.  [Effects of l-stepholidine on the central nervous and cardiovascular systems].

Authors:  Z D Zhang; G Z Jin; S X Xu; L P Yu; Y Chen; F Y Jiang; Y R Zhang; Z Sun; Y L Ding; C F Bian
Journal:  Zhongguo Yao Li Xue Bao       Date:  1986-11

4.  Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors.

Authors:  Jie Wu; Qiang Liu; Kewei Yu; Jun Hu; Yen-Ping Kuo; Marsha Segerberg; Paul A St John; Ronald J Lukas
Journal:  J Physiol       Date:  2006-07-06       Impact factor: 5.182

5.  Tetrahydroberberine inhibits acetylcholine-induced K+ current in acutely dissociated rat hippocampal CA1 pyramidal neurons.

Authors:  J Wu; G Z Jin
Journal:  Neurosci Lett       Date:  1997-01-31       Impact factor: 3.046

6.  Double target concept for smoking cessation.

Authors:  Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

7.  α6 subunit-containing nicotinic receptors mediate low-dose ethanol effects on ventral tegmental area neurons and ethanol reward.

Authors:  Scott C Steffensen; Samuel I Shin; Ashley C Nelson; Stephanie S Pistorius; Stephanie B Williams; Taylor J Woodward; Hyun Jung Park; Lindsey Friend; Ming Gao; Fenfei Gao; Devin H Taylor; M Foster Olive; Jeffrey G Edwards; Sterling N Sudweeks; Lori M Buhlman; J Michael McIntosh; Jie Wu
Journal:  Addict Biol       Date:  2017-09-13       Impact factor: 4.280

8.  U18666A, a cholesterol-inhibition agent, modulates human neuronal nicotinic acetylcholine receptors heterologously expressed in SH-EP1 cell line.

Authors:  Chao Zheng; Meng-Ya Wang; Qiang Liu; Makoto Wakui; Paul Whiteaker; Ronald J Lukas; Jie Wu
Journal:  J Neurochem       Date:  2009-02-16       Impact factor: 5.372

Review 9.  Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications.

Authors:  Jiao Mo; Yang Guo; Yu-She Yang; Jing-Shan Shen; Guo-Zhang Jin; Xuechu Zhen
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  l-tetrahydropalmatine reduces nicotine self-administration and reinstatement in rats.

Authors:  Shamia L Faison; Charles W Schindler; Steven R Goldberg; Jia Bei Wang
Journal:  BMC Pharmacol Toxicol       Date:  2016-11-07       Impact factor: 2.483

View more
  1 in total

Review 1.  A Comprehensive Review on the Chemical Properties, Plant Sources, Pharmacological Activities, Pharmacokinetic and Toxicological Characteristics of Tetrahydropalmatine.

Authors:  Qinyun Du; Xianli Meng; Shaohui Wang
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.